Mineralys Therapeutics
banner
mineralystx.com
Mineralys Therapeutics
@mineralystx.com
We're a public, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for hypertension.

mineralystx.com
In addition, our pivotal Phase 3 Launch-HTN trial was featured in the “Best of the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine (NEJM)” session.

@asnkidney.bsky.social
@jama.com

#Hypertension #CKD #CardioRenalMetabolic
#NephSky #CardioSky
jama.com JAMA @jama.com · Jun 30
In this pivotal phase 3 RCT, lorundrostat lowered blood pressure in adults with uncontrolled or treatment-resistant hypertension on multiple antihypertensive medications.

#MedSky #RCT

https://ja.ma/4nvMfbu
November 7, 2025 at 11:29 PM
Data from the Phase 3 Launch-HTN trial of lorundrostat will be featured during a session tomorrow highlighting the most impactful #kidney research articles recently published in @jama.com & @nejm.org.

#NephSky #CardioSky
November 6, 2025 at 9:47 PM
September 8, 2025 at 12:37 PM
September 4, 2025 at 8:18 PM
📌
August 30, 2025 at 11:57 AM
June 17, 2025 at 1:28 PM